AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 212.05B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 6.99B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.48 |
| PE Ratio | 30.54 |
| Forward PE | 18.27 |
| Dividend | 2.37 (1.73%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 688,288 |
| Average Volume | 2,103,195 |
| Open | 13,742 |
| Previous Close | 13,736 |
| Day's Range | 13,612 - 13,742 |
| 52-Week Range | 9,574 - 14,206 |
| Beta | 0.17 |
| RSI | 55.77 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
China’s rising biotech clout on show in flurry of billion-dollar licensing deals
Chinese drugmakers have signed a late-year burst of out-licensing agreements with overseas partners, underlining China’s growing role as a source of novel medicines as multinational pharma groups hunt...
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
Validea Detailed Fundamental Analysis - AZN
Below is Validea's guru fundamental report for ASTRAZENECA PLC (ADR) (AZN). Of the 22 guru strategies we follow, AZN rates highest using our Twin Momentum Investor model based on the published strateg...
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial
On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of o...
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market
The FDA has concluded that Andexxa's ... Full story available on Benzinga.com
AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA's Breakthrough Therapy Designation In US
(RTTNews) - AstraZeneca PLC (AZN), along with pharmaceutical company Daiichi Sankyo, Monday announced that fam-trastuzumab deruxtecan-nxki, sold under the brand name ENHERTU, has been granted the Food...
AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals
AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals
ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer
(RTTNews) - Daiichi Sankyo Co., Ltd (4568.T) and AstraZeneca Plc (AZN) announced that the U.S. FDA has granted Breakthrough Therapy Designation to ENHERTU as post-neoadjuvant therapy for adult patient...
AstraZeneca (AZN) Advances Phase 3 Trial for Enhertu in Endometrial Cancer
AstraZeneca (AZN) Advances Phase 3 Trial for Enhertu in Endometrial Cancer
AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial
The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
Dec 22 () - AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival versus standard treatments in patients with previo...
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung ...
Jacobio Pharma Signs Agreement With AstraZeneca On Pan-KRAS Inhibitor JAB-23E73
(RTTNews) - Jacobio Pharma (1167.HK) announced that it has entered into a strategic agreement with AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) for its proprietary Pan-KRAS inhibitor, JAB-23E73. Under the...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
AstraZeneca (AZN) Among Companies Prepping Price Reductions
AstraZeneca (AZN) Among Companies Prepping Price Reductions
Watch live: Trump to deliver announcement on drug pricing
President Trump on Friday afternoon will make an announcement related to lowering drug prices — an effort he has leaned into ahead of the 2026 midterm elections. In recent months, Trump has struck dea...
AstraZeneca (AZN) Withdraws Andexxa Due to Safety Concerns
AstraZeneca (AZN) Withdraws Andexxa Due to Safety Concerns
Trump to announce new drug-pricing deals later today
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
AstraZeneca's Andexxa being removed from market over safety concerns
AstraZeneca’s Andexxa will be withdrawn due to FDA concerns over serious thromboembolic risks. Read more here.
AstraZeneca: Mispriced Growth Following The Oncology Segment Success
AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now
These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.
AstraZeneca (AZN) Expands Actinium-225 Supply Agreement with Niowave
AstraZeneca (AZN) Expands Actinium-225 Supply Agreement with Niowave
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...